2nd Abu Dhabi Brain Conference 2022 Program Book

40 - 30 - 20 - 10 - 0 - REFERENCES: 1. Nurtec ODT 75 mg LPD USPI Revision date May 2021. 2. Croop R, Goadsby PJ, Stock DA, et al. E cacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394 (10200):737-745. 3. Lipton RB, Croop R, Jensen CM, et al. Rapid Decrease in Migraine Days with Rimegepant: Results From a Post Hoc Analysis of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial. Virtual Poster presented at: American Headache Society 2021 Annual Meeting; June 3-6, 2021. 4. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. Starts working quickly: signi cantly more patients get back to normal activities at 1 hour compared to placebo 2 FAST: Rapid treatment of migraine attacks and early prevention 1-3 RAPID RESPONSE Treat migraine attacks 22% n=149 16% n=108 1h † 26% n=176 38% n=255 2h ‡ 22% n=149 16% n=108 26% n=176 38% n=255 1h 32% n=216 54% n=359 2h 4h † ‡ § Placebo (n=682) Nurtec ODT 75 mg (n=669) Back to normal activities=return to normal function. Back to normal activities 2 -9.4% (95% CI: -17.1, -1.8) -30.0% (95% CI: -36.1, -23.9) Placebo (n=371) Rimegepant 75 mg (n=370) Reduction in weekly migraine days during week 1 3 II Prevent migraine attacks II Post hoc analysis of an exploratory endpoint. The analysis of this endpoint at 1 week was not tested in hierarchical order or adjusted for multiplicity. Subjects had ≥1 day of e cacy data in the observation period and in the rst week of the double-blind treatment period. 3 % REDUCTION IN WEEKLY MIGRAINE DAYS DURING WEEK 1 3 II There was a nominally greater reduction in the number of migraine days during the rst month of treatment compared to placebo (-2.9 vs -1.7, P<.0001) 4 PP-NNT-ARE-0005 0 - 10 - 20 - 30 - Adapted from Croop R, Goadsby PJ, Stock DA, et al. 2019 Adapted from Lipton RB, Croop R, Jensen CM, et al. 2021 Mean (95 % CI) percentage change